Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lexapro Prescribers: Psychiatrists (US)

Articles with lock require a subscription to GLG News | Request a free trial
June 26, 2007
Review of INTUNIV Extended Release for treatment of ADHD:
Analysis of: Shire Receives Approvable Letter from FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD | www.pipelinereview.com
Author: Lawrence Ginsberg, President, Red Oak Psychiatry Associates, P. A.
Review of INTUNIV Extended Release for treatment of ADHD: This is still another ADHD Shire drug that is efficacious and has an excellent tolerability profile. I have utilized this agent (as a principal investigator) in several clinical trials and can't wait until I am able to prescribe this agent in...
June 26, 2007
Shire (SHPGY) Expands Its ADHD Repertoire with a Promising Non-Stimulant
Analysis of: Shire Receives Approvable Letter from FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD | www.pipelinereview.com
Author: GLG Expert Contributor
Shire has received an Approvable Letter for Intuniv, guanfacine extended release formulation.  This drug may well succeed where other similar medications have failed.  The history of non-stimulants for ADHD is worth considering in this regard.
June 25, 2007
Collegium Pharmaceutical Attempts to Create a Better Oxycontin
Analysis of: Collegium Pharmaceutical Inc., Announces the Filing of IND for Abuse Deterrent Sustained Release Opioid Product | www.pipelinereview.com
Author: GLG Expert Contributor
Collegium is attempting to fill a huge need for a better long-acting form of oxycodone.  Can it deliver?
June 22, 2007
Apple (Aapl) IPhone: A Major Step Forward in Information Access for Physicians
Analysis of: Apple’s iPhone touch screen and the big picture | blogs.zdnet.com
Author: GLG Expert Contributor
The new Apple IPhone .. to be launched the end of June 2007, will be huge for the medical profession in obtaining on-the-go access to the treasure trove of medical information available on the internet.
June 21, 2007
Nuvigil may have major advantages compared to Provigil
Analysis of: Cephalon Receives FDA Approval of NUVIGIL(TM) for the Treatment of Excessive Sleepiness Associated with Three Disorders | www.pipelinereview.com
Author: GLG Expert Contributor
1. Nuvigil may have fewer side effects than Provigil 2. Nuvigil may have more rapid onset than Provigil 3. May have broader clinical applications, e.g, depression, anxiety, bipolar disorder, ADHD (adult and child), schizophrenia, etc
June 20, 2007
Cephalon (Ceph) Takes Another Swipe at Daytime Drowsiness
Analysis of: Cephalon Receives FDA Approval of NUVIGIL(TM) for the Treatment of Excessive Sleepiness Associated with Three Disorders | www.pipelinereview.com
Author: GLG Expert Contributor
Nuvigil represents the further improvement of Provigil...it is incremental in effects...will its greater cost be justified against future generics of modafinil?
June 20, 2007
Geron (Gern) Telomerase Activators and Reversing Aging - Revolutionary or Too Good to Be True?
Analysis of: Geron Increases Stake in TA Therapeutics Joint Venture | biz.yahoo.com
Author: GLG Expert Contributor
Is Geron at the forefront of impacting the aging process or just investing in a joint venture to insure its own longevity...through commercialization of a dubious technology?
June 15, 2007
Aspect Medical Systems (ASPM) vs. CNS Response (CNSO.OB) - Zero in on Depression?
Analysis of: Aspect Medical Systems' psych treatment | biotech.seekingalpha.com
Author: GLG Expert Contributor
Both Aspect Medical Systems (ASPM) and CNS Response (CNSO.OB) offer promising methods to access a patient's response to antidepressant medication without waiting the customary 3 weeks or more to see if a drug is the proper one for a particular patient.  However, there are important differences...
June 15, 2007
GlaxoSmithKline (GSK) Creates a Well-Oiled Machine
Analysis of: Over-The-Counter Weight Loss Drug Approved | abclocal.go.com
Author: GLG Expert Contributor
GlaxoSmithKline (GSK) is launching Alli, its reduced dosage Xenical, as an OTC remedy for obesity.  The public will be bombarded with marketing for this drug and the results will be quite predictable.
June 11, 2007
New biomarkers for psychiatric disorders
Analysis of: Aspect Medical Systems' psych treatment | biotech.seekingalpha.com
Author: GLG Expert Contributor
This is new era of biological psychiatry Modern technology including EEG, MRI, pharmacogenetics can help us not only better diagnose subtypes of mental illness but have potential to help predict treatment response (or lack, thereof) Having relevant biomarkers predictive of treatment response (or lack...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next81 to 90 of 157

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T09:45:16.440